Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-352847      Publish Date : Sunday, May 28, 2017 Visit : 1432

Intl. Congress form | International Congress Report | International Congress Report For Faculty | 29th Annual Congress of the European Association of Nuclear Medicine by Dr. Davood Beiki

29th Annual Congress of the European Association of Nuclear Medicine by Dr. Davood Beiki
29th Annual Congress of the European Association of Nuclear Medicine by Dr. Davood Beiki
Application Code :
306-0216-0127
 
Created Date : Tuesday, November 1, 2016-11:35 11:35:19Update Date : Tuesday, November 1, 2016-12:12 12:12:20
IP Address : 194.225.55.130Submit Date : Tuesday, November 1, 2016-12:12 12:12:35Email :beikidav@sina.tums.ac.ir
Personal Information
Name : Davood
Surname : Beiki
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Position : Professor
Tel : +98-21-88220361
Information of Congress
Title of the Congress : 29th Annual Congress of the European Association of Nuclear Medicine
Title of your Abstract : 1- 18F-FDG-Aoe-LIKKP-Pyr-A: A new peptide radiotracer for apoptosis imaging

2- Preparation and biological evaluation of 99mTc-HYNIC-LIKKPF for the detection of apoptosis
Destination Country : Spain
From : Saturday, October 15, 2016
To : Wednesday, October 19, 2016
Abstract(Please copy/paste the abstract send to the congress) : 18F-FDG-Aoe-LIKKP-Pyr-A: A new peptide radiotracer for apoptosis imaging
D. Beiki1, S. Khoshbakht2, S. Shahhosseini3, F. Kobarfard3, O. Sabzevari2, M. Amini4;
1Research Center for Nuclear Medicine, Shariati Hospital,
Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF,
2Dpartment of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences,
TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 3Dpartment of Medicinal Chemistry,
School of Pharmacy, Shahid Beheshti University of Medical Sciences, TEHRAN, IRAN,
ISLAMIC REPUBLIC OF, 4Dpartment of Medicinal Chemistry, School of Pharmacy,
Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF.

Aim: Specific biochemical changes occur in cells undergoing apoptosis that provide potential
targets for molecular imaging agents and imaging of apoptosis can provide a good way to predict
effectiveness of cancer chemotherapy. Clinical information obtained from targeting of
phosphatidyl serine (PS) would help to diagnosis and therapy of apoptosis related pathologies. A
few LIKKPF peptides with acceptable affinity for PS have been already introduced for apoptosis
imaging. We herein report the synthesis of a new LIKKPF peptide radiotracer with more affinity
for PS for detecting apoptosis.
Materials and Methods: The peptides were synthesized on solid phase using standard Fmoc
strategy, conjugated with aminooxy (Aoe), and then was considered for the radiolabeling
procedure with 18F-FDG. Biological properties were determined in vitro using camptothecin
treated Jurkat cells and in vivo using liver apoptosis mouse model induced via intraperitoneal (IP)
injection of lipopolysaccharide (LPS). Also, Log P values determination, biodistribution studies
and PET/CT imaging were performed.
Results: The radiochemical purity was >95% (100°C, 30 min, pH 5-5.5). Log P value for 18FDGAoe-
LIKKP-Pyr-A prepared by Fmoc-(4-pyridyl)-D-Ala-OH was -0.92. Kd of peptide was
determined with value 0.52 μM. Biodistribution results showed 3 times liver uptake for apoptotic
mice compared to normal mice. PET/CT images were in a good agreement with biodistribution
results. The activity ratio of liver to kidney was 0.17 and 0.61 in normal and apoptosis mouse
model, respectively.
Conclusion: 18FDG-Aoe-LIKKP-Pyr-A showed good affinity to PS and might be a potential
radiotracer for the detection of apoptosis.

18F-FDG-Aoe-LIKKP-Pyr-A: A new peptide radiotracer for apoptosis imaging
D. Beiki1, S. Khoshbakht2, S. Shahhosseini3, F. Kobarfard3, O. Sabzevari2, M. Amini4; 

1Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 2Dpartment of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 3Dpartment of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 4Dpartment of Medicinal Chemistry, School of Pharmacy, Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF. 

Aim: Specific biochemical changes occur in cells undergoing apoptosis that provide potential targets for molecular imaging agents and imaging of apoptosis can provide a good way to predict effectiveness of cancer chemotherapy. Clinical information obtained from targeting of phosphatidyl serine (PS) would help to diagnosis and therapy of apoptosis related pathologies. A few LIKKPF peptides with acceptable affinity for PS have been already introduced for apoptosis imaging. We herein report the synthesis of a new LIKKPF peptide radiotracer with more affinity for PS for detecting apoptosis.
Materials and Methods: The peptides were synthesized on solid phase using standard Fmoc strategy, conjugated with aminooxy (Aoe), and then was considered for the radiolabeling procedure with 18F-FDG. Biological properties were determined in vitro using camptothecin treated Jurkat cells and in vivo using liver apoptosis mouse model induced via intraperitoneal (IP) injection of lipopolysaccharide (LPS). Also, Log P values determination, biodistribution studies and PET/CT imaging were performed. 
Results: The radiochemical purity was >95% (100°C, 30 min, pH 5-5.5). Log P value for 18FDG-Aoe-LIKKP-Pyr-A prepared by Fmoc-(4-pyridyl)-D-Ala-OH was -0.92. Kd of peptide was determined with value 0.52 µM. Biodistribution results showed 3 times liver uptake for apoptotic mice compared to normal mice. PET/CT images were in a good agreement with biodistribution results. The activity ratio of liver to kidney was 0.17 and 0.61 in normal and apoptosis mouse model, respectively.
Conclusion: 18FDG-Aoe-LIKKP-Pyr-A showed good affinity to PS and might be a potential radiotracer for the detection of apoptosis.


Preparation and biological evaluation of 99mTc-HYNIC-LIKKPF for the detection of apoptosis
D. Beiki1, S. Khoshbakht2, S. Shahhosseini3, F. Kobarfard3, O. Sabzevari2, M. Amini4;

1Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 2Dpartment of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 3Dpartment of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, 4Dpartment of Medicinal Chemistry, School of Pharmacy, Tehran University of Medical Sciences, TEHRAN, IRAN, ISLAMIC REPUBLIC OF. 

Aim: Radioligands that have affinity and bind to phosphatidyl serine (PS) are good candidates for noninvasive imaging of apoptosis. Because of limitations of Annexin V (as a most studied imaging agent for apoptosis), there is a need to develop radioligands with better biodistribution profile for this purpose. 
Materials and Methods: HYNIC-LIKKPF was successfully synthesized via Fmoc strategy and the compound was considered for the radiolabeling procedure with Tc-99m. Then, stability and Log P values of radiopeptide were determined. Finally, binding studies, biodistribution studies and SPECT/CT imaging were performed.
Results: The radiochemical purity and Log P value were >95% and -0.92, respecteviely. 99mTc-HYNIC-LIKKPF was stable in human serum for at least 2 hr at 37ºC. Although the affinity of radiolabeled LIKKPF was less than original phage peptide, the level of binding to apoptotic cells was 2.5 times higher than control cells. Biodistribution studies showed higher liver uptake of radiopeptide in apoptotic non-treated mouse model compare to normal and pre-treated mouse. The in vivo imaging results were consistent with biodistribution studies. 
Conclusion: 99mTc-HYNIC-LIKKPF has less affinity to PS compare to original phage peptide, but high enough for specific binding to apoptotic cells in vitro and in vivo. Less affinity of radiolabeled LIKKPF might be attributed to hydrophobicity of peptide. The future peptides should be more hydrophobic compare to LIKKPF.
Keywords of your Abstract : Radiotracer, Apoptosis, FDG, Tc-99m
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/21127/Forms/306/Acceptance_2.pdf
The presentation : eposter
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/21127/Forms/306/cover_2.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/21127/Forms/306/Abstracts_2.pdf
Where has your abstract been indexed? : ISI
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : More than 6300 participants
Delegates from which countries presented in the congress? : The organizer was European Association of Nuclear Medicine and delegates from the most of countries all over the world such as Germany, Italy, Turkey, USA, UK, Poland, Hungary, Sweden, Greece, France, Spain, Netherlands, China, India, Austria, Australia, Denmark, Finland ......were presented in the congress
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : IAEA, WFNMB, SNM, AOFNMB
What were the responses to your talking points? Were specific questions or concerns raised? : I presented 2 research works at this congress and the audience showed their interests on the presented topics. 
To acknowledge the high scientific value the Scientific Programme Committee of the congress has decided to initiate for
following tracks/topics: M2M/Do.MoRe/Clinical Oncology a new feature – the so called e-posters. All
accepted papers of these 3 topics/tracks have presented as electronic posters (instead of paper posters) in the “e-Poster Area”. In this area participants found numerous computers to view the e-poster sessions alone or in small groups throughout the entire duration of the congress.
If you met staff members, please list their full names & positions. : Mohammad Eftekhari, Saeed Farzanefar, Babak Fallahi and Armaghan Fard-Esfahani form Tehran University of Medical Sciences
Vahid Dabbagh from Mashhad University of Medical Sciences
Majid Assadi from Bushehr University of Medical Sciences
Please inform us if there are any follow up actions we need to talk with the members of the congress : Congress committees put great effort into providing us with state-of-the-art Continuous Medical Education sessions, enhanced by interactive sessions. There was a long list of guest speakers who had lecture in the multidisciplinary joint symposia where the committees provided an insight into the collaborations they have established outside of nuclear medicine. The latest achievements in clinical nuclear medicine, science and technology presented and discussed during oral and poster sessions. In addition, several scientific programs (130 sessions, 2200 Abstracts) at the meeting were presented such as Plenary Sessions, Symposia, Continuing Medical Educations, Categorical Seminars, and World Summits. At the end of the meeting, the tradition of summarizing the meeting highlights in order to provide us with a broad overview of the science presented at the congress. I very much hope that the trend towards global participation and interaction will continue to develop at EANM-2016 in Barcelona.
Your experiences about the travel processes(Providing ticket, accommodation,...) : Expensive travel!!
Please give a briefing of your own observations and outcomes of the congress: : The EANM organizes a quadrennial Congress, the largest nuclear medicine meeting world-wide. The current EANM Congress was held in Barcelona, Spain, and received more than 6300 attendees with 2200 submitted abstracts. The diversity of participating countries (70 countries) and participation of scientists and experts in the field of nuclear medicine was given a good credibility to the Congress. In addition, several scientific programs (130 sessions) at the meeting were presented such as Plenary Sessions, Symposia, Continuing Medical Educations, Categorical Seminars, and World Summits.